Obsidian Therapeutics AI Stock Analysis
Want to see OBX full AI Analyst Report?
Obsidian Therapeutics (OBX) AI Stock Analysis
Obsidian Therapeutics
(NASDAQ:OBX)
The score is driven primarily by financial fundamentals: despite a significantly improved balance sheet (no debt, positive equity) and reduced operating losses, OBX remains pre-revenue with ongoing cash burn and earnings that do not appear to translate into operating cash flow. Technicals add a modest headwind due to weak near-term trend signals, while valuation looks cheap on P/E but is discounted for likely non-recurring earnings quality.
Obsidian Therapeutics (OBX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $13.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 493.80K
- Price to Earnings (P/E)
- 0.1
- Beta (1Y)
- 2.65
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 87
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Obsidian Therapeutics Business Overview & Revenue Model
Company Description
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology...
How the Company Makes Money
null
Obsidian Therapeutics Financial Statement Overview
Summary
Financial profile is mixed: the company remains pre-revenue with ongoing operating losses and continued cash burn (negative operating cash flow and negative free cash flow). The key improvement is balance-sheet repair—debt reduced to $0 and equity turning positive—plus materially narrowed EBIT losses versus prior years, but the sharp net income appears non-operating and not reflected in cash generation.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
22NegativeObsidian Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBX, the sentiment is Negative. The current price of 12.88 is below the 20-day moving average (MA) of 13.27, below the 50-day MA of 14.46, and below the 200-day MA of 14.98, indicating a bearish trend. The MACD of -0.37 indicates Negative momentum. The RSI at 46.79 is Neutral, neither overbought nor oversold. The STOCH value of 62.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OBX.
Obsidian Therapeutics Risk Analysis
Obsidian Therapeutics disclosed 47 risk factors in its most recent earnings report. Obsidian Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksObsidian Therapeutics Peers Comparison
Overall Rating
- OBX48Neutral
PASG48Neutral
LGVN46Neutral
GTBP42Neutral
CELU40Underperform
MRKR38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| OBX | 48Neutral | $848.76M | 0.05 | -210.64% | ― | ― | ― |
| PASG | 48Neutral | $12.16M | -0.39 | -377.94% | ― | ― | 28.49% |
| LGVN | 46Neutral | $9.05M | -0.33 | -223.19% | ― | -42.74% | 20.66% |
| GTBP | 42Neutral | $8.16M | -0.04 | -443.08% | ― | ― | 75.09% |
| CELU | 40Underperform | $23.07M | -0.42 | 142.25% | ― | -58.14% | 47.25% |
| MRKR | 38Underperform | $15.84M | -1.98 | -56.96% | ― | -56.64% | 64.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OBX | Obsidian Therapeutics, Inc. | 12.88 | 8.14 | 171.73% | |
| GTBP | Gt Biopharma, Inc. | 3.95 | -14.29 | -78.35% | |
| MRKR | Marker Therapeutics | 0.95 | 0.06 | 6.50% | |
| PASG | Passage Bio, Inc. | 4.00 | -4.53 | -53.11% | |
| CELU | Celularity Inc. | 0.75 | -0.84 | -52.77% | |
| LGVN | Longeveron Inc. | 3.30 | -3.60 | -52.16% |
Obsidian Therapeutics Corporate Events
Obsidian Therapeutics Completes Merger and Leadership Transition
NeutralFollowing the completion of mergers on August 3, 2026, Gazelle Parent, Inc. was renamed Obsidian Therapeutics, Inc., with Legacy Obsidian holders owning about 51.6% and PIPE investors 47.2% of the fully diluted common stock. Galera Common Stock is ex...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026